Sign In
Buy KNSA
$47.85
+0.93 (+1.98%)
At Close: Jun 03, 2026
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Kiniksa Pharmaceuticals Ltd (KNSA) Q3 2023 Earnings Call Transcript
02:35pm, Tuesday, 31'st Oct 2023
Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director, IR Sanj Patel - CEO Ross Moat - SVP and
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
10:32am, Tuesday, 31'st Oct 2023
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.18.
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
04:01pm, Tuesday, 24'th Oct 2023
HAMILTON, Bermuda, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, October 31, 2023 at 8
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
10:07am, Tuesday, 25'th Jul 2023
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16.
Kiniksa Pharmaceuticals: Autoimmune Therapy Offers Attractive Prospects At Current Price
03:25pm, Wednesday, 19'th Jul 2023
Innovations in the drug lineup, including ARCALYST, KPL-404, and Mavrilimumab, showcase Kiniksa's dedication to targeting challenging autoimmune and inflammatory conditions. ARCALYST's net product rev
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
08:00am, Monday, 17'th Jul 2023
HAMILTON, Bermuda, July 17, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30
Kiniksa Pharmaceuticals to Report Second Quarter 2023 Financial Results on July 25, 2023
02:00am, Saturday, 15'th Jul 2023
HAMILTON, Bermuda, July 18, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 25, 2023 at 8:30
3 Small-Cap Stocks That Are Worth the Gamble
08:24pm, Tuesday, 04'th Jul 2023
While your friendly financial advisor probably won't direct you to this space, small-cap stock picks can be worth your while, so long as you understand the volatility risks and don't unreasonably stre
Kiniksa Pharmaceuticals: A Somewhat Complicated Story
12:32pm, Friday, 09'th Jun 2023
Today, we take our first look at a commercial stage biopharma concern called Kiniksa Pharmaceuticals, Ltd. The company is seeing impressive growth from its primary drug asset and has an intriguing pip
Kiniksa Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
04:01pm, Tuesday, 06'th Jun 2023
HAMILTON, Bermuda, June 06, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that management will participate in a fireside chat at the Goldman Sachs 44th Annual G
Kiniksa Pharmaceuticals, Ltd. (KNSA) Q1 2023 Earnings Call Transcript
12:32pm, Saturday, 06'th May 2023
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA ) Q1 2023 Earnings Conference Call May 2, 2023 8:30 AM ET Company Participants Rachel Frank - Head of Investor Relations Sanj Patel - Chief Executive Officer
Kiniksa Pharmaceuticals to Report First Quarter 2023 Financial Results on May 2, 2023
04:01pm, Monday, 01'st May 2023
HAMILTON, Bermuda, May 01, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 2, 2023, at 8:30 a
7 Thrilling Biotech Stocks for Aggressive Investors to Buy
01:40pm, Wednesday, 05'th Apr 2023
While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts
7 Small-Cap Stocks to Buy for Explosive Growth Potential
02:20pm, Thursday, 30'th Mar 2023
While most financial advisors will direct you to a healthy portion of established, large-capitalization enterprises, small-cap stocks to buy provide extra oomph for willing participants. For example,
